Next Article in Journal
Functional Assessment of Genetically Modified Infrapatellar Fat Pad Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles (EVs): Potential Implications for Inflammation/Pain Reversal in Osteoarthritis
Previous Article in Journal
Age-Dependent Regulation of Acetylcholine Release at the Neuromuscular Junction Mediated by GABA
Previous Article in Special Issue
The Calprotectin Fragment, CPa9-HNE, Is a Plasma Biomarker of Mild Chronic Obstructive Pulmonary Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 14
Issue 24
10.3390/cells14241950
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Altered Sphingolipids, Glycerophospholipids, and Lysophospholipids Reflect Disease Status in Idiopathic Steroid-Sensitive Nephrotic Syndrome in Children: A Non-Targeted Metabolomic Study

by
Takahiro Kanai
1,
Hideo Ogiso
2,
Jun Aoyagi
1,
Masanori Kurosaki
1,
Tomomi Maru
1,
Marika Ishii
1,
Kazuya Tanimoto
1,
Mitsuaki Yoshino
1,
Yuri Yamashita
1,
Toshihiro Tajima
1,
Ryozo Nagai
3 and
Kenichi Aizawa
2,4,*
1
Department of Pediatrics, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke 329-0498, Tochigi, Japan
2
Department of Translational Research, Clinical Research Center, Jichi Medical University Hospital, 3311-1, Yakushiji, Shimotsuke 329-0498, Tochigi, Japan
3
Jichi Medical University, 3311-1, Yakushiji, Shimotsuke 329-0498, Tochigi, Japan
4
Clinical Pharmacology Center, Jichi Medical University Hospital, 3311-1, Yakushiji, Shimotsuke 329-0498, Tochigi, Japan
*
Author to whom correspondence should be addressed.
Cells 2025, 14(24), 1950; https://doi.org/10.3390/cells14241950
Submission received: 29 October 2025 / Revised: 26 November 2025 / Accepted: 2 December 2025 / Published: 9 December 2025
(This article belongs to the Special Issue Biomarkers in Human Diseases and Emerging Diagnostic Technologies for Their Identification and Application)
Browse Figures
Versions Notes

Abstract

Idiopathic steroid-sensitive nephrotic syndrome (ISSNS) is the most common glomerular disease in children, yet its molecular mechanisms and lipid-mediated pathophysiology remain poorly understood. In this study, we performed comprehensive non-targeted metabolomic analysis of serum samples obtained from children with ISSNS during both the nephrotic and remission phases to identify metabolic alterations associated with disease status. Using liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF-MS), we profiled low-molecular-weight metabolites and identified significant alterations in several lipid classes, including sphingolipids, glycerophospholipids, and lysophospholipids. Several sphingomyelin and phosphatidylcholine species showed strong correlations with total cholesterol levels, reflecting lipid alterations consistent with the hyperlipidemic state that characterizes ISSNS. In contrast, oxidized phosphatidylcholines may more specifically reflect oxidative membrane injury and glomerular permeability changes associated with disease status. These findings highlight membrane lipid remodeling as a key feature of active disease and suggest potential lipid-based biomarkers for disease monitoring and therapeutic evaluation in pediatric ISSNS. This study provides a metabolomic framework for understanding lipid-driven mechanisms of ISSNS pathophysiology.

1. Introduction

Idiopathic steroid-sensitive nephrotic syndrome (ISSNS) is the most common glomerular disease in children [1]. Its incidence is 1.4–6.1 per 100,000 children [2], with a male-to-female ratio of 1.8:1 [3]. ISSNS is characterized by heavy proteinuria due to dysfunction of the glomerular filtration barrier, to hypoalbuminemia (<3.0 g/dL) caused by urinary protein loss, and to hypercholesterolemia, in the absence of underlying diseases. Even though steroid monotherapy can induce complete remission within 4 weeks [4], the mechanism by which steroids achieve this effect remains unclear [1]. Furthermore, the pathophysiology of ISSNS itself is still poorly understood. Consequently, no curative therapy has been established, and approximately 80% of patients experience relapse [4]. Therefore, understanding the pathophysiology of pediatric ISSNS is essential.
Previous studies have suggested that sera from patients with ISSNS contain pathogenic factors [5]. For example, administration of supernatant from peripheral blood mononuclear cell cultures derived from patients with minimal change nephrotic syndrome (MCNS), which typically presents as steroid-sensitive nephrotic syndrome, can induce proteinuria [6]. Furthermore, plasma apheresis treatment, such as low-density lipoprotein (LDL) apheresis and/or double-filtration plasmapheresis, can induce remission in MCNS without steroids or other medications [7].
To identify these factors, comprehensive serum analysis using non-targeted metabolomics is required. This methodology enables detection of changes in metabolite profiles between the nephrotic and remission phases of pediatric ISSNS. Liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) is a powerful tool for comprehensive serum metabolomics. Metabolite profiling of sera, which has been instrumental in revealing the pathophysiology of pediatric ISSNS, can reveal distinct metabolic signatures associated with disease status.
Two studies have applied non-targeted metabolomics to investigate serum metabolite profiles associated with disease status in pediatric nephrotic syndrome. They identified metabolites and pathways related to the tricarboxylic acid cycle, amino acid metabolism, bile acid biosynthesis, linoleate metabolism, and glyoxylate and dicarboxylate metabolism [8], as well as metabolites such as D-mannitol, dulcitol, D-sorbitol, and xanthosine monophosphate [9]. However, these studies did not provide definitive insights into the pathophysiology of pediatric ISSNS. Their limitations included: (i) a heterogenous study populations (idiopathic nephrotic syndrome may include idiopathic steroid-resistant nephrotic syndrome, the pathophysiology of which differs from that of ISSNS) [8]; (ii) non-standardized timing of sample collection with or without steroid treatment; (iii) comparisons limited to sera from children with ISSNS during the nephrotic phase and those from healthy controls, without comparisons between nephrotic and remission phases [9]; and (iv) exclusive use of a normal-phase hydrophilic interaction chromatography (HILIC) [9], which is not suited to strongly non-polar compounds.
To overcome these limitations, we analyzed serum metabolite profiles using paired samples collected from pediatric ISSNS patients during both the nephrotic and remission phases, without steroid treatment. Both C18 and HILIC columns were employed in positive and negative ion modes to ensure comprehensive coverage.

2. Patients and Methods

2.1. Patients

Inclusion criteria were as follows: (i) pediatric ISSNS, defined as remission achieved within 4 weeks of treatment with prednisolone at 2 mg/kg/day (maximum 60 mg/day) in the absence of underlying diseases [4]; (ii) selectivity index < 0.1, measured by the clearance ratio of IgG/transferrin; (iii) no infection for 1 week prior to the study to avoid confounding effects of infection; and (iv) no immunosuppressant for 6 months prior to this study, to exclude the confounding influence of immunosuppressants. The nephrotic phase was defined as urinary protein > 300 mg/dL in a morning sample on three consecutive days [10]. The remission phase was defined as a urinary protein/creatinine ratio (UP/UCr) < 0.2 g/g·Cr on the three consecutive days [10]. Nephrotic phase samples were collected before initiation of steroid treatment or albumin administration. Remission phase samples were collected when patients were not receiving steroids or immunosuppressants. Definitions of steroid-sensitive nephrotic syndrome, nephrotic phase, and remission phase were based on IPNA clinical practice recommendations [4]. Secondary SSNS and steroid-resistant nephrotic syndrome were excluded.
A total of 22 paired samples from 14 patients (10 males, 4 females; median age 4 years, range 1–14 years) were included with samples collected during both the nephrotic and remission phases. Of these, 15 samples were collected from 7 patients during different clinical courses. Patient profiles were similar to those reported in previous studies of pediatric ISSNS, including a male/female ratio of 2.5:1 [3], and an allergic complication rate of 43% (6/14 patients; food allergy 1, asthma 2, hay fever 3) [11]. No patients had comorbidities other than the allergies described above, and none were taking anti-allergic medications at the time of blood collection. The median UP/UCr was 7.8 g/g·Cr (range, 1.7–17.6 g/g·Cr) in the nephrotic phase. The median serum albumin level was 2.7 g/dL (range, 0.7–4.0 g/dL) in the nephrotic phase, and was 4.2 g/dL (range, 2.9–4.1 g/dL) in the remission phase. The median total cholesterol level was 234 mg/dL (range, 151–520 mg/dL) in the nephrotic phase, and was 162.5 mg/dL (range, 136–294 mg/dL) in the remission phase. These differences were statistically significant (both p < 0.01). Serum samples were obtained from blood samples collected from patient antecubital veins and were not treated before freezing. No sample derivation was performed prior to analysis.

2.2. Methods

2.2.1. Sample Preparation for LC-MS/MS Metabolomics

Serum samples were stored at −80 °C and thawed immediately prior to use. Fifty microliters of serum were mixed with 250 μL of methanol in a 1.5 mL polypropylene vial. After vigorous shaking, samples were centrifuged (12,000× g for 10 min at 4 °C), after which 50 μL of the upper layer were mixed with 200 μL of methanol/ultra-pure water (1:1, v/v) in a new 1.5 mL polypropylene vial. Samples were again centrifuged after shaking (12,000× g for 5 min at 4 °C), and then 200 μL of the upper layer were collected in a 0.3 mL polypropylene vial. Polypropylene vials previously washed with methanol were used for all preparations.

2.2.2. Non-Targeted Metabolomic Analysis Using LC-QTOF-MS

Liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis was performed using an LCMS9030 system (Shimadzu, Kyoto, Japan) based on a previously reported method [12] with minor modification. Serum metabolites were separated on a YMC-Accura Triart C18 column (100 mm × 2.1 mm, 1.9 μm; YMC Corporation, Kyoto, Japan). Mobile phases A and B consisted of 0.1% (v/v) formic acid in ultra-pure water and 0.1% (v/v) formic acid in acetonitrile/methanol (1:1, v/v), respectively. The solvent gradient was as follows: 0% B for 1 min followed by a linear gradient to 5% B from 1 to 3 min, to 90% B from 3 to 7 min, and to 100% B from 7 to 11 min, held at 100% B from 11 to 15 min. Subsequently, the mobile phase was returned to initial conditions over 0.5 min and maintained for 4.5 min until the end of the run. The oven temperature was 45 °C, and the flow rate was 0.32 mL/min. The sample volume injected was 2 μL.
For analysis of hydrophilic metabolites, LC separation was additionally performed using a normal-phase (HILIC) column (ZIC-p HILIC; 100 mm × 2.1 mm, 5 μm; SeQuant, Darmstadt, Germany). Mobile phases A and B consisted of 10 mM ammonium bicarbonate in ultra-pure water, pH 9.2, and acetonitrile/2-propanol/methanol (255:30:15, v/v/v), respectively. The initial buffer composition was 95% B, decreasing linearly to 60% B from 0 min to 8 min and to 5% B from 8 min to 10 min. It was then maintained at 5% B from 10 min to 12 min. Subsequently, the mobile phase was returned to the initial conditions over 0.5 min and maintained for 7.5 min until the end of the run. The oven temperature was 40 °C, and the flow rate was 0.27 mL/min. The sample volume injected was 2 μL.
MS data were acquired in both positive (pos) and negative (neg) ion modes over the usual range of 70 to 900 m/z using electrospray ionization. MS parameters were used with default settings as follows: interface voltage of 4.5 kV (pos) and −3.5 kV (neg), interface temperature of 300 °C, nebulization gas flow of 3 L/min, heating gas flow of 10 L/min, drying gas flow of 3 L/min, heat block temperature of 400 °C, and DL temperature of 250 °C. Before sample measurements, m/z values were calibrated using a calibrant (ESI Tuning Mix for Ion Trap, Sigma-Aldrich, St. Louis, MO, USA) so that mass accuracy throughout data collection was within 10 ppm. One representative among samples tested was used as a quality control (QC) sample. The QC sample was injected five times in total at the beginning, middle, and end of each batch to check stability of detection amounts during measurements (Supplementary Table S1), confirming that peak detection was stable during sample measurement. The relative abundance of each component was evaluated by the peak intensity of the parent ion (MS1) in full scan mode. Additional measurements were also made in data-dependent auto MS/MS mode to obtain fragmentation ions (MS2) necessary for structure estimation. Fragmentation was performed using argon as a collision gas at a collision energy of 30 eV with a spread of 15 eV. MS2 spectra were generated simultaneously for the top five MS1 ions with an m/z range between 70 and 900, surpassing an intensity threshold of 2000. Data were collected using LabSolutions software version 5.118 for LCMS9030 (Shimadzu).

2.3. Data Processing and Statistical Analysis

After converting acquired data into xml files, peak detection and alignment were performed using MS-DIAL (version 5.1) to assign peak IDs [13]. Compound names were then annotated using both MS-DIAL and MS-FINDER (version 3.56) [14]. As necessary, MS1 ions were searched against the HMDB metabolite database (version 5.0, accessed on 28 May 2025), MassBank of North America (accessed on 28 May 2025), MetFrag (accessed on 28 May 2025), and the LIPID MAPS lipid database (accessed on 28 May 2025). If MS2 spectra matched one blood metabolite, this compound was annotated as Rank A. If a significant MS2 spectrum could not be obtained, but the MS1 value matched the only metabolite registered in HMDB, it was also annotated as Rank A. If MS1 and/or MS2 spectra matched, but could not be resolved to a single compound due to multiple candidate metabolite hits, a compound that we judged most likely to be a serum metabolite was annotated as Rank B (Supplementary Figure S1).
Selection and refinement of metabolites were performed as shown in Figure 1. Over 30,000 peaks were detected by LC-QTOF-MS in serum metabolic analyses. Prior to multivariate analysis, peaks exhibiting high variability or minimal differences between the nephrotic and remission groups were manually excluded. Subsequently, important metabolic features distinguishing the two groups were selected using partial least squares discriminant analysis (PLS-DA) in MetaboAnalyst (version 6.0, accessed on 28 May 2025). Non-targeted metabolomics and extraction of characteristic components described above were performed by referring to previous reports [8,9,15,16,17]. A flow diagram summarizing the number of samples screened and analyzed is shown in Figure 1.

3. Results

3.1. Multivariate Analysis Reveals Metabolic Differences Between Nephrotic and Remission Phases

Score plots generated from oPLS-DA, sPLS-DA, and PLS-DA demonstrated a trend toward separation between the nephrotic and remission phases (Figure 2) when analyzed using both C18 and HILIC columns under positive and negative ion modes. Four representative score plots are shown in Figure 2. Multivariate analyses enabled clear discrimination between the two groups across all four measurements, revealing differences in serum metabolites. From these analyses, 75 metabolic features were initially selected as contributors to the group separation.

3.2. Identification of Metabolites That Differ Between Disease Phases

While primary selection was performed using PLS-DA, secondary selection for each of the 75 metabolic features involved univariate significance testing (q < 0.05) and fold-change analysis (|FC| > 1.5 or <0.5) between the two groups. Subsequent compound annotation identified 23 and 12 metabolites as Rank A and Rank B, respectively (Table 1 and Table 2). MS/MS spectrum searches for five non-lipid compounds among the 23 Rank A annotations are presented in Supplementary Figure S1. This analysis demonstrated that serum metabolites that were elevated in the nephrotic phase and reduced in remission included oxidized phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs), and sphingomyelins (SMs) (Table 1), whereas those that were decreased in the nephrotic phase and elevated in remission included indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF), [(4-{3-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]-4,6-dihydroxy-2-methoxyphenyl}[17]-2-methylbut-2-en-1-yl)oxy]sulfonic acid (DPMPS), (2-{9-hydroxy-2-oxo-2H,8H,9H-furo[2,3-h]chromen-8-yl}-2-[(3-methylbut-2-enoyl)oxy]propoxy)sulfonic acid (HOCPS), and indoxyl sulfate (Table 2). These metabolites are summarized in Table 3.

3.3. Correlation Analysis with Clinical Parameters

To assess clinical relevance, Spearman’s rank correlation analysis was conducted between metabolite intensities and key clinical parameters: UP/UCr, serum albumin, and total cholesterol levels (Table 4, Figure 3 and Figure 4). For UP/UCr ratios, two metabolites including SM (d34:2) showed strong positive correlations (ρ ≥ 0.6), whereas CMPF exhibited a strong negative correlation (ρ ≤ −0.6). Correlations with serum albumin revealed strong negative associations for four metabolites including SM (d34:2) and SM (d32:1) (ρ ≤ −0.6), and strong positive associations for indoxyl sulfate, CMPF, DPMPS, and HOCPS (ρ ≥ 0.6). For serum total cholesterol, strong positive correlations were observed with six metabolites including multiple SM species and LPE (18:0) (ρ ≥ 0.6), while CMPF, DPMPS, HOCPS and indoxyl sulfate showed strong negative correlations (ρ ≤ −0.6).

4. Discussion

This study demonstrated that sphingolipids (sphingomyelins), glycerophospholipids (phosphatidylcholine), lysophospholipids (lysophosphatidylcholine and lysophosphatidylethanolamine), and uremic toxins (CMPF and indoxyl sulfate) reflect the disease status of ISSNS in children. Serum levels of these lipids were elevated, whereas levels of uremic toxins were decreased during the nephrotic phase compared with the remission phase. Therefore, these sphingolipids, glycerophospholipids, lysophospholipids and uremic toxins may serve as biomarkers for pediatric ISSNS. To the best of our knowledge, this is the first report to demonstrate a simultaneous association between these lipid classes, uremic toxins, and disease status of pediatric ISSNS.
There is a close metabolic relationship between sphingomyelin, phosphatidylcholine, and lysophosphatidylcholine. Sphingomyelin is generated by transferring phosphocholine from phosphatidylcholine to ceramide. Phosphatidylcholine is synthesized from lysophosphatidylcholine by lysophosphatidylcholine acyltransferase, whereas lysophosphatidylcholine is generated from phosphatidylcholine by phospholipase A2. Additionally, these sphingolipids, glycerophospholipids, and lysophospholipids are components of the outer leaflet of cell membranes [18], and are important in podocyte function, cholesterol homeostasis, immune regulation, and platelet activation through lipid-mediated signaling pathways [19]. Hyperlipidemia, immune dysregulation, and platelet activation are major complications of pediatric ISSNS, suggesting that lipid alterations contribute to disease pathophysiology.

4.1. Sphingomyelin and Proteinuria Mediated Podocyte Dysfunction

In this study, SM (d34:2) intensities in serum were positively correlated with UP/UCr ratios. Sphingolipids contribute to formation of mechanically stable and chemically resistant outer leaflets of cell membrane lipid bilayers and are an important component of lipid rafts, particularly in podocytes. These rafts are essential for podocyte signaling, membrane trafficking, and cytoskeletal organization [20]. Podocytes are terminally differentiated glomerular epithelial cells, which form the glomerular filtration barrier. Consequently, podocyte dysfunction leads to abnormal glomerular filtration, resulting in proteinuria and nephrotic syndrome. Indeed, sphingomyelin accumulation and dysfunction in podocytes reportedly causes proteinuria in Niemann–Pick disease [21,22]. Furthermore, decreased expression of sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b) has been reported in patients with pediatric idiopathic nephrotic syndrome during the nephrotic phase, compared with those in remission and with controls [23]. SMPDL-3b is expressed at the plasma membrane, particularly in podocytes, where it hydrolyzes sphingomyelin into ceramide and phosphocholine. Thus, decreased SMPDL-3b expression results in sphingomyelin accumulation and dysfunction. Because decreased SMPDL-3b expression alone does not directly impair podocyte function, sphingomyelin accumulation likely renders podocytes more susceptible to dysfunction [24], thereby contributing to proteinuria. Moreover, rituximab, a monoclonal antibody that protects against proteinuria in pediatric ISSNS, reportedly prevents decreased SMPLD-3b expression in podocytes [25]. Taken together, elevated serum sphingomyelin levels may reflect podocyte dysfunction and injury. Therefore, serum sphingomyelin levels may correlate with the degree of proteinuria and serum albumin levels.

4.2. Dysregulation of Cholesterol Homeostasis Induced by Sphingomyelin, Phosphatidylcholine, and Lysophosphatidylcholine

In this study, serum levels of sphingomyelin, phosphatidylcholine, and lysophosphatidylcholine were elevated during the nephrotic phase compared with the remission phase. These lipids are also components of both LDL and high-density lipoprotein (HDL) particles. Although their relative proportions vary depending on the study population and analytical methodology, LDL is generally enriched in sphingomyelin and phosphatidylcholine, whereas HDL contains predominantly phosphatidylcholine [26,27,28]. Serum LDL levels are elevated in the nephrotic phase of pediatric ISSNS compared with remission, whereas HDL levels remain unchanged [29,30]. This observation suggests that the altered serum levels of sphingomyelin, phosphatidylcholine, and lysophosphatidylcholine between the two phases are primarily attributable to LDL. In nephrotic syndrome, mechanistically, increased LDL synthesis [31] and reduced LDL catabolism due to impaired lipoprotein lipase activity [32] have been proposed as underlying mechanisms. Thus, podocyte dysfunction in pediatric ISSNS may cause proteinuria and increased serum sphingolipid concentrations, which in turn may contribute to elevated serum LDL levels.

4.3. Immunological Effects of Sphingomyelin, Phosphatidylcholine, and Lysophosphatidylcholine

Sphingomyelin, phosphatidylcholine and lysophosphatidylcholine affect immune regulation through T cells, B cells, and macrophages, and activation of these cells is well established as a major pathogenic mechanism of pediatric ISSNS [33,34,35].
Sphingolipid metabolism generates lipid second messengers that regulate key stages of immune cell development, differentiation, activation, proliferation, and function [36]. For example, sphingomyelin metabolism in T cells affects T cell function and development of T cell-mediated immunity [37] and both sphingomyelin and phosphatidylcholine promote growth of B lymphocytes through raftophilic species [38].
Phosphatidylcholine further promotes gamma-delta T cell activation [39] and modulates T cell responses [40]. In macrophages, phosphatidylcholine induces robust changes in gene expression, leading to their activation [41]. Moreover, lysophosphatidylethanolamine (LPE) also promotes T cell differentiation [42]. Also, sphingomyelin activates macrophages by stabilizing raft microdomains that cluster Fcγ receptors [43].
Lysophosphatidylcholine additionally activates resting T cells, leading to IL-2 production and IL-2 receptor expression [44]. Consistently, serum IL-2 levels are elevated during the nephrotic phase in pediatric ISSNS [45]. Lysophosphatidylcholine also activates B cells and enhances antibody production by modulating membrane dynamics and amplifying B cell receptor-mediated signaling. This process leads to upregulation of genes required for B cell differentiation and immunoglobulin secretion [46].

4.4. Phosphatidylcholine and Mechanisms of Platelet Activation

Phosphatidylcholine is a precursor of platelet activating factor (PAF) synthesis [47]. Therefore, elevated phosphatidylcholine levels may lead to increase PAF production, contributing to platelet activation and thrombus formation, which are also common complications of pediatric ISSNS [48]. Furthermore, PAF also increases vascular permeability and induces vasodilatation [49], both of which are relevant to pediatric ISSNS pathophysiology [50]. Indeed, plasma PAF concentrations are significantly higher in the nephrotic phase compared with the remission phase and control patients [51]. Sphingomyelin-rich domains in platelets provide platforms for fibrin–actomyosin interactions, thereby contributing to clot retraction [52], which is one of the complications of pediatric ISSNS. Lysophosphatidylcholine is a major component of platelet-derived microvesicles. Via its interaction with G2AR on platelets, it contributes to platelet activation and ultimately to vascular inflammation [53].

4.5. Association of Sphingolipids and CMPF with Clinical Parameters

This study further revealed that sphingolipid, SM (d34:2), showed strong correlation with UP/UCr ratios, serum albumin, and total cholesterol levels, all of which are closely related to pediatric ISSNS pathophysiology. As stated previously, sphingolipids are essential for maintaining structural and functional integrity of podocytes [54], injuries to which cause proteinuria. Therefore, sphingolipids may be involved not only in disease status, but also in the underlying pathophysiology of pediatric ISSNS. Podocyte dysfunction may be one of the reasons why serum sphingolipid levels were associated with these parameters; however, this cannot be confirmed based on the present findings. Nonetheless, the findings of this study collectively suggest that specific sphingolipids and related metabolites are closely associated with clinical markers of disease status, highlighting their potential role as biomarkers or contributors to the pathophysiology of pediatric ISSNS.
In addition, this study also revealed that uremic toxin CMPF (Supplementary Figure S2) shows strong negative correlations with UP/UCr ratios, serum albumin, and total cholesterol levels. CMPF is a compound that accumulates as the glomerular filtration rate (GFR) decreases and is known as one of the protein-bound uremic toxins (PBUTs) that bind almost completely (approximately 100%) to serum albumin [55,56]. Indoxyl sulfate (Supplementary Figure S3) is another uremic toxin that accumulates with reduced GFR and is a representative protein-bound uremic toxin that binds strongly (90–98%) to serum albumin [55,56]. In children with ISSNS, GFR remains within the normal range. Therefore, the negative correlation of serum CMPF and indoxyl sulfate levels with serum albumin concentration, and their positive correlation with the UP/UCr, are thought to reflect an increase in unbound CMPF and indoxyl sulfate in the nephrotic phase, when hypoalbuminemia results from urinary albumin loss. Correlations between uremic toxins and total cholesterol levels may be a secondary effect due to nephrotic condition. Therefore, these uremic toxins (CMPF and indoxyl sulfate) are likely secondary to the disease process of pediatric ISSNS rather than primary causative factors.
CPMeF (Supplementary Figure S4), a minor derivative belonging to the same family as CMPF, has been detected in blood and urine; however, its reference levels have not been established, and its physiological or pathological significance remains largely unknown (Human Metabolome Database, Version 5.0). In addition, chemical compounds of HOCPS (Supplementary Figure S5) and DPMPS (Supplementary Figure S6) are currently not identifiable in standard chemical databases such as PubChem or ChemSpider. Further investigation is required to determine their roles in pediatric ISSNS.

4.6. Oxidized Phosphatidylcholine and Pediatric ISSNS

Increased levels of oxidized phosphatidylcholine (OxPC) species during the nephrotic phase suggest an association with the disease status of pediatric ISSNS. OxPCs themselves can directly cause endothelial dysfunction, independent of oxidized LDL-mediated mechanisms [57]. Children with FRNS and SDNS have endothelial dysfunction during relapse, which is largely dependent upon disease status [58]. Moreover, their accumulation may represent a functional lipid alteration contributing to the pathophysiology of pediatric ISSNS [59]. This finding supports the notion that oxidative modification of membrane lipids may exacerbate pediatric ISSNS [60].
Additionally, oxidized LDL, which contains phosphatidylcholine and sphingomyelin as major lipid components, can also cause endothelial dysfunction that may lead to proteinuria [61].
Overall, multivariate and correlation analyses provide robust evidence that metabolic alterations are phase-dependent, reproducible across chromatographic and ionization conditions, and closely linked to disease-relevant clinical parameters. Integration of these findings enables identification of key lipid classes and metabolites with potential mechanistic significance in pediatric ISSNS.

5. Limitations

This study has several limitations. First, intensities of sphingolipids, glycerophospholipids and lysophospholipids were not compared with those in other forms of nephrotic syndrome or in healthy controls. Therefore, it cannot be concluded that the increases observed are specific to pediatric ISSNS. Indeed, Erkan et al. reported increased lysophosphatidylcholines in patients with FSGS [62]. Second, this study was not designed as an intervention trial to evaluate effects of these lipid classes in pediatric ISSNS. Thus, we cannot assert that the observed associations cause pediatric ISSNS. Third, the small sample size (n = 14 patients) is a major limitation that affects the generalizability and statistical power of the study. Finally, in this study, non-targeted metabolomic analysis was employed for exploratory purposes. However, implementation of LC-MS-based metabolomics and lipidomics in routine clinical settings faces several challenges. The most critical issue is the lack of inter-laboratory standardization, as results may vary among institutions. To ensure reproducibility and clinical applicability, establishment of standardized targeted aLC-MS methods using stable isotope-labeled internal standards will be essential in the future.

6. Conclusions

Sphingolipids, glycerophospholipids, and lysophospholipids appear to be involved in pediatric ISSNS disease status. These lipid classes are linked to hyperlipidemia, immune dysregulation, and platelet activation, and may thereby contribute to the pathophysiology of pediatric ISSNS. Further investigations are needed to clarify underlying mechanisms and pathogenic processes of this disease.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells14241950/s1, Figure S1: How to annotate as Rank A and B title; Figure S2: Spectrum of CMPF and the structural formula; Figure S3: Spectrum of Indoxyl sulfate and the structural formula; Figure S4: Spectrum of CPMeF and the structural formula; Figure S5: Spectrum of HOCPS and the structural formula; Figure S6: Spectrum of DPMPS and the structural formula. Table S1: Reproducibility of detection peaks for representative metabolites in QC samples.

Author Contributions

Conceptualization, T.K., T.T. and R.N.; Methodology, K.A.; Software, H.O.; Validation, K.A. and H.O.; Formal Analysis, T.K. and H.O.; Investigation, T.K.; Resources, T.K. and K.A.; Data Curation, T.K., J.A., M.K., T.M., M.I., K.T., M.Y. and Y.Y.; Writing—Original Draft Preparation, T.K.; Writing—Review and Editing, R.N. and K.A.; Visualization, T.K.; Supervision, T.T. and R.N.; Project Administration, T.K.; Funding Acquisition, T.K. and K.A. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported partially by the Kawano Masanori Memorial Foundation for the Promotion of Pediatrics, The Japan Foundation for Pediatric Research, and JSPS KAKENHI Grant Number 25460697, 16K10073, and 19K08328.

Institutional Review Board Statement

This study complies with the Declaration of Helsinki, and was approved by the Ethics Committee of Jichi Medical University (approval code: 24-141, approval date: 15 January 2025). All procedures performed were in accordance with ethical standards of the institutional and/or national research committees at which studies were conducted. Written, informed consent of participants was not required for this study. To notify patients of this study, we put an announcement on our website: https://www.jichi.ac.jp/scci/disclosure/shonika/ (accessed on 17 January 2025).

Informed Consent Statement

Not applicable. It is not required to obtain consent from participants in this study and publication. To notify patients about this study, we put an announcement on our web site: https://www.jichi.ac.jp/scci/disclosure/shonika/ (accessed on 17 January 2025).

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding author.

Acknowledgments

We thank all patients and their guardians for participating in this study.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Vivarelli, M.; Gibson, K.; Sinha, A.; Boyer, O. Childhood Nephrotic Syndrome. Lancet 2023, 402, 809–824. [Google Scholar] [CrossRef]
  2. Veltkamp, F.; Rensma, L.R.; Bouts, A.H.M. Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-Analysis. Pediatrics 2021, 148, e2020029249. [Google Scholar] [CrossRef] [PubMed]
  3. International Study of Kidney Disease in Children. Nephrotic Syndrome in Children: Prediction of Histopathology from Clinical and Laboratory Characteristics at Time of Diagnosis. A Report of the International Study of Kidney Disease in Children. Kidney Int. 1978, 13, 159–165. [CrossRef]
  4. Trautmann, A.; Boyer, O.; Hodson, E.; Bagga, A.; Gipson, D.S.; Samuel, S.; Wetzels, J.; Alhasan, K.; Banerjee, S.; Bhimma, R.; et al. IPNA Clinical Practice Recommendations for the Diagnosis and Management of Children with Steroid-Sensitive Nephrotic Syndrome. Pediatr. Nephrol. 2023, 38, 877–919. [Google Scholar] [CrossRef]
  5. Shalhoub, R.J. Pathogenesis of Lipoid Nephrosis: A Disorder of T-Cell Function. Lancet 1974, 2, 556–560. [Google Scholar] [CrossRef] [PubMed]
  6. Maruyama, K.; Tomizawa, S.; Shimabukuro, N.; Fukuda, T.; Johshita, T.; Kuroume, T. Effect of Supernatants Derived from T Lymphocyte Culture in Minimal Change Nephrotic Syndrome on Rat Kidney Capillaries. Nephron 1989, 51, 73–76. [Google Scholar] [CrossRef]
  7. Kobayashi, T.; Ando, Y.; Umino, T.; Miyata, Y.; Muto, S.; Hironaka, M.; Asano, Y.; Kusano, E. Complete Remission of Minimal-Change Nephrotic Syndrome Induced by Apheresis Monotherapy. Clin. Nephrol. 2006, 65, 423–426. [Google Scholar] [CrossRef] [PubMed]
  8. Guo, J.; Zhao, J.; Liu, R.; Yu, J.; Zhang, M.; Wang, H.; Liu, L. Metabolomics Analysis of Serum in Pediatric Nephrotic Syndrome Based on Targeted and Non-Targeted Platforms. Metabolomics 2021, 17, 38. [Google Scholar] [CrossRef]
  9. Hu, L.; Lin, L.; Huang, G.; Xie, Y.; Peng, Z.; Liu, F.; Bai, G.; Li, W.; Gao, L.; Wang, Y.; et al. Metabolomic Profiles in Serum and Urine Uncover Novel Biomarkers in Children with Nephrotic Syndrome. Eur. J. Clin. Investig. 2023, 53, e13978. [Google Scholar] [CrossRef]
  10. Hogg, R.J.; Portman, R.J.; Milliner, D.; Lemley, K.V.; Eddy, A.; Ingelfinger, J. Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations from a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE). Pediatrics 2000, 105, 1242–1249. [Google Scholar] [CrossRef]
  11. Meadow, S.R.; Sarsfield, J.K. Steroid-Responsive and Nephrotic Syndrome and Allergy: Clinical Studies. Arch. Dis. Child. 1981, 56, 509–516. [Google Scholar] [CrossRef]
  12. Ogiso, H.; Miura, K.; Nagai, R.; Osaka, H.; Aizawa, K. Non-Targeted Metabolomics Reveal Apomorphine’s Therapeutic Effects and Lysophospholipid Alterations in Steatohepatitis. Antioxidants 2024, 13, 1293. [Google Scholar] [CrossRef]
  13. Tsugawa, H.; Cajka, T.; Kind, T.; Ma, Y.; Higgins, B.; Ikeda, K.; Kanazawa, M.; VanderGheynst, J.; Fiehn, O.; Arita, M. MS-DIAL: Data-Independent Ms/Ms Deconvolution for Comprehensive Metabolome Analysis. Nat. Methods 2015, 12, 523–526. [Google Scholar] [CrossRef]
  14. Tsugawa, H.; Kind, T.; Nakabayashi, R.; Yukihira, D.; Tanaka, W.; Cajka, T.; Saito, K.; Fiehn, O.; Arita, M. Hydrogen Rearrangement Rules: Computational Ms/Ms Fragmentation and Structure Elucidation Using MS-FINDER Software. Anal. Chem. 2016, 88, 7946–7958. [Google Scholar] [CrossRef]
  15. Ramabulana, A.T.; Petras, D.; Madala, N.E.; Tugizimana, F. Metabolomics and Molecular Networking to Characterize the Chemical Space of Four Momordica Plant Species. Metabolites 2021, 11, 763. [Google Scholar] [CrossRef]
  16. Saigusa, D.; Okamura, Y.; Motoike, I.N.; Katoh, Y.; Kurosawa, Y.; Saijyo, R.; Koshiba, S.; Yasuda, J.; Motohashi, H.; Sugawara, J.; et al. Establishment of Protocols for Global Metabolomics by LC-MS for Biomarker Discovery. PLoS ONE 2016, 11, e0160555. [Google Scholar] [CrossRef] [PubMed]
  17. Jacob, M.; Nimer, R.M.; Alabdaljabar, M.S.; Sabi, E.M.; Al-Ansari, M.M.; Housien, M.; Sumaily, K.M.; Dahabiyeh, L.A.; Abdel Rahman, A.M. Metabolomics Profiling of Nephrotic Syndrome Towards Biomarker Discovery. Int. J. Mol. Sci. 2022, 23, 12614. [Google Scholar] [CrossRef]
  18. Wuthier, R.E. Lipid Composition of Isolated Epiphyseal Cartilage Cells, Membranes and Matrix Vesicles. Biochim. Biophys. Acta 1975, 409, 128–143. [Google Scholar] [CrossRef]
  19. Jendrasiak, G.L.; Smith, R.L. The Effect of the Choline Head Group on Phospholipid Hydration. Chem. Phys. Lipids 2001, 113, 55–66. [Google Scholar] [CrossRef] [PubMed]
  20. Valsecchi, M.; Cazzetta, V.; Oriolo, F.; Lan, X.; Piazza, R.; Saleem, M.A.; Singhal, P.C.; Mavilio, D.; Mikulak, J.; Aureli, M. APOL1 Polymorphism Modulates Sphingolipid Profile of Human Podocytes. Glycoconj. J. 2020, 37, 729–744. [Google Scholar] [CrossRef] [PubMed]
  21. Grafft, C.A.; Fervenza, F.C.; Semret, M.H.; Orloff, S.; Sethi, S. Renal Involvement in Neimann-Pick Disease. NDT Plus 2009, 2, 448–451. [Google Scholar] [CrossRef]
  22. Pintavorn, P.; Munie, S.; Munagapati, S. Lamellar Bodies in Podocytes Associated With Compound Heterozygous Mutations for Niemann Pick Type C1 Mimicking Fabry Disease, a Case Report. Can. J. Kidney Health Dis. 2022, 9, 20543581221124635. [Google Scholar] [CrossRef]
  23. Watanabe, S.; Hirono, K.; Aizawa, T.; Tsugawa, K.; Joh, K.; Imaizumi, T.; Tanaka, H. Podocyte Sphingomyelin Phosphodiesterase Acid-Like 3b Decreases among Children with Idiopathic Nephrotic Syndrome. Clin. Exp. Nephrol. 2021, 25, 44–51. [Google Scholar] [CrossRef]
  24. Merscher, S.; Fornoni, A. Podocyte Pathology and Nephropathy—Sphingolipids in Glomerular Diseases. Front. Endocrinol. 2014, 5, 127. [Google Scholar] [CrossRef]
  25. Tasaki, M.; Shimizu, A.; Hanekamp, I.; Torabi, R.; Villani, V.; Yamada, K. Rituximab Treatment Prevents the Early Development of Proteinuria Following Pig-to-Baboon Xeno-Kidney Transplantation. J. Am. Soc. Nephrol. 2014, 25, 737–744. [Google Scholar] [CrossRef]
  26. Subbaiah, P.V.; Liu, M. Role of Sphingomyelin in the Regulation of Cholesterol Esterification in the Plasma Lipoproteins. Inhibition of Lecithin-Cholesterol Acyltransferase Reaction. J. Biol. Chem. 1993, 268, 20156–20163. [Google Scholar] [CrossRef] [PubMed]
  27. Hevonoja, T.; Pentikäinen, M.O.; Hyvönen, M.T.; Kovanen, P.T.; Ala-Korpela, M. Structure of Low Density Lipoprotein (LDL) Particles: Basis for Understanding Molecular Changes in Modified Ldl. Biochim. Biophys. Acta 2000, 1488, 189–210. [Google Scholar] [CrossRef] [PubMed]
  28. Huang, R.; Silva, R.A.; Jerome, W.G.; Kontush, A.; Chapman, M.J.; Curtiss, L.K.; Hodges, T.J.; Davidson, W.S. Apolipoprotein a-I Structural Organization in High-Density Lipoproteins Isolated from Human Plasma. Nat. Struct. Mol. Biol. 2011, 18, 416–422. [Google Scholar] [CrossRef] [PubMed]
  29. Dowerah, P.; Gogoi, A.; Shira, C.D.; Sarkar, B.; Mazumdar, S. A Study of Dyslipidemia and Its Clinical Implications in Childhood Nephrotic Syndrome. Cureus 2023, 15, e47434. [Google Scholar] [CrossRef]
  30. Kanai, T.; Yamagata, T.; Ito, T.; Odaka, J.; Saito, T.; Aoyagi, J.; Momoi, M.Y. Apolipoprotein Aii Levels Are Associated with the up/Ucr Levels in Idiopathic Steroid-Sensitive Nephrotic Syndrome. Clin. Exp. Nephrol. 2015, 19, 107–113. [Google Scholar] [CrossRef]
  31. de Sain-van der Velden, M.G.; Kaysen, G.A.; Barrett, H.A.; Stellaard, F.; Gadellaa, M.M.; Voorbij, H.A.; Reijngoud, D.J.; Rabelink, T.J. Increased Vldl in Nephrotic Patients Results from a Decreased Catabolism While Increased Ldl Results from Increased Synthesis. Kidney Int. 1998, 53, 994–1001. [Google Scholar] [CrossRef]
  32. Joven, J.; Villabona, C.; Vilella, E.; Masana, L.; Albertí, R.; Vallés, M. Abnormalities of Lipoprotein Metabolism in Patients with the Nephrotic Syndrome. N. Engl. J. Med. 1990, 323, 579–584. [Google Scholar] [CrossRef]
  33. Kanai, T.; Shiraishi, H.; Yamagata, T.; Ito, T.; Odaka, J.; Saito, T.; Aoyagi, J.; Momoi, M.Y. Th2 Cells Predominate in Idiopathic Steroid-Sensitive Nephrotic Syndrome. Clin. Exp. Nephrol. 2010, 14, 578–583. [Google Scholar] [CrossRef]
  34. Kanai, T.; Yamagata, T.; Momoi, M.Y. Macrophage Inflammatory Protein-1beta and Interleukin-8 Associated with Idiopathic Steroid-Sensitive Nephrotic Syndrome. Pediatr. Int. 2009, 51, 443–447. [Google Scholar] [CrossRef] [PubMed]
  35. Kemper, M.J.; Meyer-Jark, T.; Lilova, M.; Müller-Wiefel, D.E. Combined T- and B-Cell Activation in Childhood Steroid-Sensitive Nephrotic Syndrome. Clin. Nephrol. 2003, 60, 242–247. [Google Scholar] [CrossRef]
  36. Cinque, B.; Di Marzio, L.; Centi, C.; Di Rocco, C.; Riccardi, C.; Grazia Cifone, M. Sphingolipids and the Immune System. Pharmacol. Res. 2003, 47, 421–437. [Google Scholar] [CrossRef] [PubMed]
  37. Beyersdorf, N.; Müller, N. Sphingomyelin Breakdown in T Cells: Role in Activation, Effector Functions and Immunoregulation. Biol. Chem. 2015, 396, 749–758. [Google Scholar] [CrossRef]
  38. Tóth, E.A.; Oszvald, Á.; Péter, M.; Balogh, G.; Osteikoetxea-Molnár, A.; Bozó, T.; Szabó-Meleg, E.; Nyitrai, M.; Derényi, I.; Kellermayer, M.; et al. Nanotubes Connecting B Lymphocytes: High Impact of Differentiation-Dependent Lipid Composition on Their Growth and Mechanics. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2017, 1862, 991–1000. [Google Scholar] [CrossRef]
  39. Li, Y.; Wang, Y.; Shi, F.; Zhang, X.; Zhang, Y.; Bi, K.; Chen, X.; Li, L.; Diao, H. Phospholipid Metabolites of the Gut Microbiota Promote Hypoxia-Induced Intestinal Injury Via Cd1d-Dependent γδ T Cells. Gut Microbes 2022, 14, 2096994. [Google Scholar] [CrossRef]
  40. Rusnak, T.; Azarcoya-Barrera, J.; Makarowski, A.; Jacobs, R.L.; Richard, C. Plant- and Animal-Derived Dietary Sources of Phosphatidylcholine Have Differential Effects on Immune Function in the Context of a High-Fat Diet in Male Wistar Rats. J. Nutr. 2024, 154, 1936–1944. [Google Scholar] [CrossRef] [PubMed]
  41. Cauvi, D.M.; Hawisher, D.; Derunes, J.; Rodriguez, E.; De Maio, A. Membrane Phospholipids Activate the Inflammatory Response in Macrophages by Various Mechanisms. Faseb J. 2024, 38, e23619. [Google Scholar] [CrossRef]
  42. Ma, X.C.; Clardy, J. Spontaneous Generation of an Endogenous RORγt Agonist. J. Am. Chem. Soc. 2025, 147, 11688–11692. [Google Scholar] [CrossRef]
  43. Bryan, A.M.; You, J.K.; Li, G.; Kim, J.; Singh, A.; Morstein, J.; Trauner, D.; Pereira de Sá, N.; Normile, T.G.; Farnoud, A.M.; et al. Cholesterol and Sphingomyelin Are Critical for Fcγ Receptor-Mediated Phagocytosis of Cryptococcus Neoformans by Macrophages. J. Biol. Chem. 2021, 297, 101411. [Google Scholar] [CrossRef]
  44. Asaoka, Y.; Oka, M.; Yoshida, K.; Sasaki, Y.; Nishizuka, Y. Role of Lysophosphatidylcholine in T-Lymphocyte Activation: Involvement of Phospholipase A2 in Signal Transduction through Protein Kinase C. Proc. Natl. Acad. Sci. USA 1992, 89, 6447–6451. [Google Scholar] [CrossRef] [PubMed]
  45. Shimoyama, H.; Nakajima, M.; Naka, H.; Maruhashi, Y.; Akazawa, H.; Ueda, T.; Nishiguchi, M.; Yamoto, Y.; Kamitsuji, H.; Yoshioka, A. Up-Regulation of Interleukin-2 mRNA in Children with Idiopathic Nephrotic Syndrome. Pediatr. Nephrol. 2004, 19, 1115–1121. [Google Scholar] [CrossRef] [PubMed]
  46. Ngwenya, B.Z.; Foster, D.M. Enhancement of Antibody Production by Lysophosphatidylcholine and Alkylglycerol. Proc. Soc. Exp. Biol. Med. 1991, 196, 69–75. [Google Scholar] [CrossRef] [PubMed]
  47. Snyder, F. Cdp-Choline:Alkylacetylglycerol Cholinephosphotransferase Catalyzes the Final Step in the de Novo Synthesis of Platelet-Activating Factor. Biochim. Biophys. Acta 1997, 1348, 111–116. [Google Scholar] [CrossRef]
  48. Eneman, B.; Levtchenko, E.; van den Heuvel, B.; Van Geet, C.; Freson, K. Platelet Abnormalities in Nephrotic Syndrome. Pediatr. Nephrol. 2016, 31, 1267–1279. [Google Scholar] [CrossRef]
  49. Jackson, C.V.; Schumacher, W.A.; Kunkel, S.L.; Driscoll, E.M.; Lucchesi, B.R. Platelet-Activating Factor and the Release of a Platelet-Derived Coronary Artery Vasodilator Substance in the Canine. Circ. Res. 1986, 58, 218–229. [Google Scholar] [CrossRef]
  50. Garin, E.H. Circulating Mediators of Proteinuria in Idiopathic Minimal Lesion Nephrotic Syndrome. Pediatr. Nephrol. 2000, 14, 872–878. [Google Scholar] [CrossRef]
  51. Hüseyinov, A.; Kantar, M.; Mir, S.; Coker, I.; Kabasakal, C.; Cura, A. Plasma and Urinary Platelet Activating Factor Concentrations and Leukotriene Releasing Activity of Leukocytes in Steroid Sensitive Nephrotic Syndrome of Childhood. Acta Paediatr. Jpn. 1998, 40, 57–62. [Google Scholar] [CrossRef]
  52. Komatsuya, K.; Kaneko, K.; Kasahara, K. Function of Platelet Glycosphingolipid Microdomains/Lipid Rafts. Int. J. Mol. Sci. 2020, 21, 5539. [Google Scholar] [CrossRef]
  53. Diehl, P.; Nienaber, F.; Zaldivia, M.T.K.; Stamm, J.; Siegel, P.M.; Mellett, N.A.; Wessinger, M.; Wang, X.; McFadyen, J.D.; Bassler, N.; et al. Lysophosphatidylcholine Is a Major Component of Platelet Microvesicles Promoting Platelet Activation and Reporting Atherosclerotic Plaque Instability. Thromb. Haemost. 2019, 119, 1295–1310. [Google Scholar] [CrossRef]
  54. Li, G.; Kidd, J.; Gehr, T.W.B.; Li, P.L. Podocyte Sphingolipid Signaling in Nephrotic Syndrome. Cell. Physiol. Biochem. 2021, 55, 13–34. [Google Scholar] [CrossRef]
  55. Meijers, B.K.; Bammens, B.; Verbeke, K.; Evenepoel, P. A Review of Albumin Binding in CKD. Am. J. Kidney Dis. 2008, 51, 839–850. [Google Scholar] [CrossRef] [PubMed]
  56. Shi, Y.; Tian, H.; Wang, Y.; Shen, Y.; Zhu, Q.; Ding, F. Improved Dialysis Removal of Protein-Bound Uraemic Toxins with a Combined Displacement and Adsorption Technique. Blood Purif. 2022, 51, 548–558. [Google Scholar] [CrossRef] [PubMed]
  57. Rikitake, Y.; Hirata, K.; Kawashima, S.; Inoue, N.; Akita, H.; Kawai, Y.; Nakagawa, Y.; Yokoyama, M. Inhibition of Endothelium-Dependent Arterial Relaxation by Oxidized Phosphatidylcholine. Atherosclerosis 2000, 152, 79–87. [Google Scholar] [CrossRef] [PubMed]
  58. Zwołińska, D.; Grzeszczak, W.; Szczepańska, M.; Kiliś-Pstrusińska, K.; Szprynger, K. Lipid Peroxidation and Antioxidant Enzymes in Children on Maintenance Dialysis. Pediatr. Nephrol. 2006, 21, 705–710. [Google Scholar] [CrossRef]
  59. Santos, M.; Maurício, T.; Domingues, R.; Domingues, P. Impact of Oxidized Phosphatidylcholine Supplementation on the Lipidome of Raw264.7 Macrophages. Arch. Biochem. Biophys. 2025, 768, 110384. [Google Scholar] [CrossRef]
  60. Sreelatha, S.; D’souza, B.; D’souza, V.; Rajendiran, K. Role of Oxidant-Antioxidant Enzymes in Managing the Cardiovascular Risks in Nephrotic Syndrome Patients. J. Nephropathol. 2022, 11, e17276. [Google Scholar] [CrossRef]
  61. Dąbkowski, K.; Kreft, E.; Sałaga-Zaleska, K.; Chyła-Danił, G.; Mickiewicz, A.; Gruchała, M.; Kuchta, A.; Jankowski, M. Human In Vitro Oxidized Low-Density Lipoprotein (Oxldl) Increases Urinary Albumin Excretion in Rats. Int. J. Mol. Sci. 2024, 25, 5498. [Google Scholar] [CrossRef] [PubMed]
  62. Erkan, E.; Zhao, X.; Setchell, K.; Devarajan, P. Distinct Urinary Lipid Profile in Children with Focal Segmental Glomerulosclerosis. Pediatr. Nephrol. 2016, 31, 581–588. [Google Scholar] [CrossRef] [PubMed]
Cells 14 01950 g001
Figure 1. Screening Procedure for Serum Metabolites in Non-Targeted Metabolomics. Metabolomic features in serum samples were selected using various PLS-DA methods (o-PLS-DA, s-PLS-DA) to discover possible biomarkers for pediatric ISSNS.
Figure 1. Screening Procedure for Serum Metabolites in Non-Targeted Metabolomics. Metabolomic features in serum samples were selected using various PLS-DA methods (o-PLS-DA, s-PLS-DA) to discover possible biomarkers for pediatric ISSNS.
Cells 14 01950 g001
Cells 14 01950 g002
Figure 2. Multivariate analyses distinguishing the nephrotic and remission phases of pediatric ISSNS. (a) Orthogonal partial least squares discriminant analysis (oPLS-DA) using a C18 column in positive ion mode; (b) Sparse partial least squares discriminant analysis (sPLS-DA) using a C18 column in negative ion mode; (c) Orthogonal partial least squares discriminant analysis (oPLS-DA) using a HILIC column in positive ion mode; (d) Partial least squares discriminant analysis (PLS-DA) using a HILIC column in negative ion mode. Score plots for all analyses are shown for comparison between nephrotic and remission phases. Data points for the nephrotic phase are shown in red, and those for the remission phase are shown in green.
Figure 2. Multivariate analyses distinguishing the nephrotic and remission phases of pediatric ISSNS. (a) Orthogonal partial least squares discriminant analysis (oPLS-DA) using a C18 column in positive ion mode; (b) Sparse partial least squares discriminant analysis (sPLS-DA) using a C18 column in negative ion mode; (c) Orthogonal partial least squares discriminant analysis (oPLS-DA) using a HILIC column in positive ion mode; (d) Partial least squares discriminant analysis (PLS-DA) using a HILIC column in negative ion mode. Score plots for all analyses are shown for comparison between nephrotic and remission phases. Data points for the nephrotic phase are shown in red, and those for the remission phase are shown in green.
Cells 14 01950 g002
Cells 14 01950 g003
Figure 3. Correlations between serum sphingomyelin (d34:2) levels and clinical parameters in pediatric ISSNS. (a) Urinary protein-to-creatinine (UP/UCr) ratios; (b) serum albumin levels; (c) serum total cholesterol levels. Scatter plots show the relationships between sphingomyelin (d34:2) peak intensities and each clinical parameter. Spearman’s correlation coefficients (ρ) are indicated, and regression lines are shown.
Figure 3. Correlations between serum sphingomyelin (d34:2) levels and clinical parameters in pediatric ISSNS. (a) Urinary protein-to-creatinine (UP/UCr) ratios; (b) serum albumin levels; (c) serum total cholesterol levels. Scatter plots show the relationships between sphingomyelin (d34:2) peak intensities and each clinical parameter. Spearman’s correlation coefficients (ρ) are indicated, and regression lines are shown.
Cells 14 01950 g003
Cells 14 01950 g004
Figure 4. Correlations between serum 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) levels and clinical parameters in pediatric ISSNS. (a) Urinary protein-to-creatinine (UP/UCr) ratios; (b) serum albumin levels; (c) serum total cholesterol levels. Scatter plots show the relationships between CMPF peak intensities and each clinical parameter. Spearman’s correlation coefficients (ρ) are indicated, and regression lines are shown.
Figure 4. Correlations between serum 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) levels and clinical parameters in pediatric ISSNS. (a) Urinary protein-to-creatinine (UP/UCr) ratios; (b) serum albumin levels; (c) serum total cholesterol levels. Scatter plots show the relationships between CMPF peak intensities and each clinical parameter. Spearman’s correlation coefficients (ρ) are indicated, and regression lines are shown.
Cells 14 01950 g004
Table 1. Annotated metabolites and putatively annotated compounds with increased intensity in the nephrotic phase of pediatric ISSNS (fold change > 1.5, q ≤ 0.05 vs. remission phase).
Table 1. Annotated metabolites and putatively annotated compounds with increased intensity in the nephrotic phase of pediatric ISSNS (fold change > 1.5, q ≤ 0.05 vs. remission phase).
Annotated
Compounds		FCp Valuesq ValuesAdduct Typem/zLC
Mode		RT
(min)
PC(16:0/18:2)+O5.5990.0268020.044286[M+HCOO]−818.563C1811.281
PC(16:0/22:6)+2O5.0490.0258740.041429[M+HCOO]−882.557C1811.096
PC(18:0/18:2)+O4.2070.0174780.04[M+HCOO]−846.593C1812.076
LPC(17:0)3.0380.0039030.028571[M+HCOO]−554.351C189.3
LPC(18:0)2.3290.0021040.024286[M+HCOO]−568.367C189.479
PC(16:0/20:3)2.3190.0070690.034286[M+HCOO]−828.583C1813.633
LPE(18:0)1.8480.0024070.027143[M−H]−480.313C189.679
PC(16:0/22:4)1.6850.0104410.037143[M+HCOO]−854.597C1813.608
LPC(20:2)1.6610.0001490.011429[M+HCOO]−592.367C189.22
LPC(16:0)1.6390.0002520.014286[M+HCOO]−540.335C188.819
SM(d34:2)1.6080.0001360.008571[M+HCOO]−745.556C1812.654
SM(d33:1)1.5770.0003230.015714[M+HCOO]−733.556C1812.697
PC(18:0/20:2)1.5760.0001410.01[M+HCOO]−858.631C1815.066
PC(35:1)1.540.0000850.007143[M+HCOO]−818.599C1814.435
SM(d34:1)1.5340.0004830.018571[M+HCOO−C2H4O2]−687.55C1812.976
PC(18:1/20:3)1.5220.0061560.031429[M+HCOO]−854.598C1813.454
SM(d32:1)1.5190.0011160.022857[M+HCOO]−719.541C1812.257
PC(38:3)1.50.0063320.032857[M+HCOO]−856.605C1813.455
ΔFA(18:1)+3O7.7380.0462040.05[M−H]−329.236C187.358
ΔcPA(16:0)5.6930.0053250.03[M−H]−391.228C188.987
ΔPyroglutamylglycine3.3040.0125980.038571[M+H]+187.073HILIC2.902
ΔGlutamylglutamate2.4050.0000320.002857[M+H]+277.109HILIC0.961
ΔPyroglutaminylglutamine or Methylcytidine2.240.0350830.048571[M+H]+258.111HILIC3.043
ΔPyroglutamylglycine2.2040.0286010.047143[M+H]+187.073HILIC2.766
Δc-Glutamylglutamic acid1.8580.0084480.035714[M+H]+277.104HILIC6.346
ΔAsparaginylvaline1.7510.026290.042857[M+H]+232.131HILIC3.044
ΔPC(34:2)1.6930.0283820.045714[M+H]+758.616C1813.249
ΔSM(d18:1/16:0)+O1.6360.0000410.004286[M+HCOO]−763.568C1811.783
ΔPC(36:2)1.5450.0021770.025714[M+H]+786.607C1813.409
Legend: The top 10 metabolites (by absolute fold change among those with q ≤ 0.05 in Rank A) are highlighted in bold. Δ denotes metabolites annotated as Rank B. q-values were calculated using the Benjamini–Hochberg false discovery rate (FDR) procedure to adjust for multiple comparisons among the 35 tested metabolites. Abbreviations: FC, fold change (mean nephrotic/remission ratio); p value, p value from Welch’s t-test; LC mode, separation mode in liquid chromatography; RT, retention time; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; SM, sphingomyelin; FA, fatty acid; cPA, cyclic phosphatidic acid; PC(16:0/22:6)+2O, oxidized form of PC(16:0/22:6) with two additional oxygen atoms.
Table 2. Annotated metabolites and putatively identified compounds showing decreased intensity in the nephrotic phase of ISSNS (fold change < 0.5, q ≤ 0.05 vs. nephrotic phase).
Table 2. Annotated metabolites and putatively identified compounds showing decreased intensity in the nephrotic phase of ISSNS (fold change < 0.5, q ≤ 0.05 vs. nephrotic phase).
Annotated
Compounds		FCp Valuesq ValuesAdduct
Type		m/zLC ModeRT (min)
CMPeF0.2490.000010.0014286[M−H]−267.1245C187.879
CMPF0.2640.0000660.0057143[M−H]−239.094C187.376
DPMPS0.2670.0005490.02[M−H]−453.088HILIC2.581
HOCPS0.340.0005570.0214286[M−H]−439.072HILIC2.822
Indoxyl sulfate0.4920.0003370.0171429[M−H]−212.004C185.606
ΔPDMS0.4610.0001510.0128571[M+H]+536.17C1812.809
Legend: Boldface indicates metabolites annotated as Rank A with q ≤ 0.05. Δ denotes metabolites annotated as Rank B. Abbreviations: FC, fold change (mean nephrotic/remission ratio); p value, p-value from Welch’s t-test; LC mode, separation mode in liquid chromatography; RT, retention time; CMPeF, 3-carboxy-4-methyl-5-pentyl-2-furanpropionic acid; CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid; DPMPS, [(4-{3-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]-2,4,6-trihydroxyphenyl}-2-methylbut-2-en-1-yl)oxy]sulfonic acid; HOCPS, (2-{9-hydroxy-2-oxo-2H,8H,9H-furo[2,3-h]chromen-8-yl}-2-[(3-methylbut-2-enoyl)oxy]propoxy)sulfonic acid; PMDS, polydimethylsiloxane.
Table 3. Classification of lipid classes and urinary toxins, with abbreviations and full names.
Table 3. Classification of lipid classes and urinary toxins, with abbreviations and full names.
ClassificationFull NamesAbbreviation
Lipid classesSphingolipidsSphingomyelinSM
GlycerophospholipidsPhosphatidylcholinePC
LysophospholipidsLysophosphatidylcholineLPC
LysophosphatidylethanoamineLPE
Uremic toxins 3-carboxy-4-methyl-5-propyl-2-furanpropionic acidCPMF
Indoxyl sulfate
Table 4. Spearman’s correlations between metabolite intensities and urinary protein-to-creatinine (UP/UCr) ratio, serum albumin, and total cholesterol levels in pediatric ISSNS.
Table 4. Spearman’s correlations between metabolite intensities and urinary protein-to-creatinine (UP/UCr) ratio, serum albumin, and total cholesterol levels in pediatric ISSNS.
Annotated CompoundsFCCorrelation Efficient
UP/UCrSerum AlbSerum T.chol
SM(d34:2)1.6080.611−0.6480.676
LPE(18:0)1.848 0.606
SM(d33:1)1.577 0.684
SM(d34:1)1.534 0.632
SM(d32:1)1.519 −0.6340.698
CMPeF0.249−0.7250.831−0.752
CMPF0.264−0.6060.747−0.836
DPMPS0.267 0.768−0.725
HOCPS0.340 0.679−0.657
Indoxyl sulfate0.492 0.719
ΔSM(d18:1/16:0)+O1.6360.646−0.6240.699
ΔGlutamylglutamate2.405 −0.606
Legend: Boldface indicates metabolites annotated as Rank A in pediatric ISSNS. Δ denotes metabolites annotated as Rank B. Spearman’s correlation coefficients were calculated between metabolite intensities and UP/UCr, serum albumin, and total cholesterol levels. Positive correlations indicate higher metabolite levels associated with increased clinical parameter values, whereas negative correlations indicate inverse relationships. Abbreviations: FC, fold change (mean nephrotic/remission ratio); UP/UCr, urinary protein/creatinine ratio; Alb, albumin; T.chol, total cholesterol; SM, sphingomyelin; LPE, lysophosphatidylethanolamine; CMPeF, 3-carboxy-4-methyl-5-pentyl-2-furanpropionic acid; CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid; DPMPS, [(4-{3-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]-4,6-dihydroxy-2-methoxyphenyl}-2-methylbut-2-en-1-yl)oxy]sulfonic acid; HOCPS, (2-{9-hydroxy-2-oxo-2H,8H,9H-furo[2,3-h]chromen-8-yl}-2-[(3-methylbut-2-enoyl)oxy]propoxy)sulfonic acid; PMDS, polydimethylsiloxane; PMDS, polydimethylsiloxane; SM(d18:1/16:0)+O, oxidized form of SM(d18:1/16:0) with one additional oxygen atom.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kanai, T.; Ogiso, H.; Aoyagi, J.; Kurosaki, M.; Maru, T.; Ishii, M.; Tanimoto, K.; Yoshino, M.; Yamashita, Y.; Tajima, T.; et al. Altered Sphingolipids, Glycerophospholipids, and Lysophospholipids Reflect Disease Status in Idiopathic Steroid-Sensitive Nephrotic Syndrome in Children: A Non-Targeted Metabolomic Study. Cells 2025, 14, 1950. https://doi.org/10.3390/cells14241950

AMA Style

Kanai T, Ogiso H, Aoyagi J, Kurosaki M, Maru T, Ishii M, Tanimoto K, Yoshino M, Yamashita Y, Tajima T, et al. Altered Sphingolipids, Glycerophospholipids, and Lysophospholipids Reflect Disease Status in Idiopathic Steroid-Sensitive Nephrotic Syndrome in Children: A Non-Targeted Metabolomic Study. Cells. 2025; 14(24):1950. https://doi.org/10.3390/cells14241950

Chicago/Turabian Style

Kanai, Takahiro, Hideo Ogiso, Jun Aoyagi, Masanori Kurosaki, Tomomi Maru, Marika Ishii, Kazuya Tanimoto, Mitsuaki Yoshino, Yuri Yamashita, Toshihiro Tajima, and et al. 2025. "Altered Sphingolipids, Glycerophospholipids, and Lysophospholipids Reflect Disease Status in Idiopathic Steroid-Sensitive Nephrotic Syndrome in Children: A Non-Targeted Metabolomic Study" Cells 14, no. 24: 1950. https://doi.org/10.3390/cells14241950

APA Style

Kanai, T., Ogiso, H., Aoyagi, J., Kurosaki, M., Maru, T., Ishii, M., Tanimoto, K., Yoshino, M., Yamashita, Y., Tajima, T., Nagai, R., & Aizawa, K. (2025). Altered Sphingolipids, Glycerophospholipids, and Lysophospholipids Reflect Disease Status in Idiopathic Steroid-Sensitive Nephrotic Syndrome in Children: A Non-Targeted Metabolomic Study. Cells, 14(24), 1950. https://doi.org/10.3390/cells14241950

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop